ClinicalTrials.gg
Sign In

Prostatic Neoplasms, Castration-Resistant clinical trials

The registry lists 85 studies for Prostatic Neoplasms, Castration-Resistant across more than 10 countries. 28 are recruiting or about to start. 73 of them are mainly about Prostatic Neoplasms, Castration-Resistant (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Prostatic Neoplasms, Castration-Resistant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
26
Recruiting
25
Terminated
11
Active, not recruiting
10
Withdrawn
5
Status unknown
3

Phase

Phase 1
33
Phase 2
30
Phase 3
10
Phase 4
3
Early Phase 1
1

Where

United States
50
Spain
21
France
19
Australia
19
United Kingdom
18
Italy
13

Who runs them

Janssen Research & Development, LLC (8) · Bayer (7) · Novartis Pharmaceuticals (6) · MacroGenics (4) · Nuvation Bio Inc. (3) · Michael Graham PhD, MD (3) · Hoffmann-La Roche (2) · Radboud University Medical Center (2)

What is being tested here

Drugs under test in Prostatic Neoplasms, Castration-Resistant studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Pasritamig222
Enzalutamide106
Abiraterone114
Abiraterone Acetate113
Darolutamide102
Safimaltib101
Ibrutinib101
JNJ-64264681101
Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543101
Ifinatamab deruxtecan101

Drug classes tested here Antiandrogens 2 open · Immune checkpoint inhibitors 7 · Antimitotic agents 5

Coming up

4phase 3 studies under way
11studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 25 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (88%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (4%) take children under 18. 0 (0%) are for women only and 20 (80%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 25
AgeWomenMen
100 (0%)1 (4%)
185 (20%)25 (100%)
305 (20%)25 (100%)
405 (20%)25 (100%)
505 (20%)25 (100%)
655 (20%)25 (100%)
755 (20%)25 (100%)
855 (20%)25 (100%)

Across all 85 studies, recruiting or not: 0% stop at 75 or younger and 0% at 65; 6% take children; 0% are for women only and 82% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting1

Studies

Recruiting first, then most recently updated. Showing 50 of 85. Browse all 85 → or search them.